Cohance Lifesciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+89.4%+13.9%−21.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+13.8%−7.5%−28.4%
−19.5%−15.2%−32.3%
−43.3%−11.8%−27.0%
−55.4%−10.8%−27.0%
+89.0%+34.5%+14.7%
+119.2%−10.2%+18.2%
+27.8%−19.6%−20.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹18,416 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-21.6+13.9+89.4—
EBITDA Growth—-28.4-7.5+13.8—
EBIT Growth—-32.3-15.2-19.5—
Net Income Growth—-27.0-11.8-43.3—
EPS Growth—-27.0-10.8-55.4—
Total Assets Growth—+14.7+34.5+89.0—
Total Equity Growth—+18.2-10.2+119.2—
Cash from Operations Growth—-20.5-19.6+27.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.